Key Takeaways From Guardant Health Analyst Ratings
Portfolio Pulse from Benzinga Insights
Guardant Health (NASDAQ:GH) has received a range of analyst ratings over the past three months, with a majority being bullish. Analysts have raised their 12-month price targets, reflecting an average target of $39.67, up from $35.43. The company has shown strong revenue growth but faces challenges with profitability and debt management.
August 08, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guardant Health has received predominantly bullish ratings from analysts, with several raising their price targets. The average 12-month price target is now $39.67, indicating positive sentiment. However, the company faces challenges with profitability and debt management.
The majority of analysts have given bullish ratings and raised their price targets for Guardant Health, indicating positive sentiment. The company's strong revenue growth supports this outlook. However, challenges with profitability and debt management may temper the positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100